IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 81,783 shares of the medical research company’s stock after selling 3,826 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in IQVIA were worth $16,071,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth approximately $1,616,000. Nordea Investment Management AB increased its position in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. bought a new stake in IQVIA in the fourth quarter valued at $941,000. Fifth Third Bancorp grew its position in shares of IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after acquiring an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS increased its holdings in shares of IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after acquiring an additional 2,700 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on IQV shares. UBS Group reduced their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Stephens started coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Citigroup cut their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Stock Performance

Shares of NYSE IQV opened at $177.27 on Friday. IQVIA Holdings Inc. has a 52-week low of $176.03 and a 52-week high of $253.84. The stock has a market capitalization of $31.25 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock’s fifty day simple moving average is $193.15 and its 200 day simple moving average is $206.47.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.